RVXC.F Stock Overview
A late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Resverlogix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.034 |
| 52 Week High | CA$0.068 |
| 52 Week Low | CA$0.029 |
| Beta | 0.71 |
| 1 Month Change | -6.52% |
| 3 Month Change | -14.00% |
| 1 Year Change | -32.75% |
| 3 Year Change | -91.63% |
| 5 Year Change | -96.30% |
| Change since IPO | -98.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| RVXC.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.2% | 2.1% | 2.8% |
| 1Y | -32.7% | -3.8% | 24.5% |
Return vs Industry: RVXC.F underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: RVXC.F underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| RVXC.F volatility | |
|---|---|
| RVXC.F Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RVXC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RVXC.F's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Don McCaffrey | www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
Resverlogix Corp. Fundamentals Summary
| RVXC.F fundamental statistics | |
|---|---|
| Market cap | US$10.75m |
| Earnings (TTM) | -US$11.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs RVXC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVXC.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.23m |
| Earnings | -US$11.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -93.0% |
How did RVXC.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:02 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Resverlogix Corp. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Zavoico | MLV & Co LLC |
| Claude Camiré | Paradigm Capital, Inc. |
| Simos Simeonidis | Rodman & Renshaw, LLC |